Accuray Incorporated — FY2019 Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2019. The request metadata says “2018 Q4,” but the supplied filing is the FY2019 10-K; its quarterly data include FY2019 Q4, ended June 30, 2019. Unless stated otherwise, amounts below are in U.S. dollars.
Business context
Accuray develops, manufactures, sells, and services radiation oncology systems, principally CyberKnife robotic radiosurgery and TomoTherapy systems, including Radixact. Services are a substantial recurring component of revenue. The company operates in a competitive, capital-equipment market and reported that 68% of FY2019 revenue came from outside the Americas.
Financial results and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Net revenue | $418.8 million | $404.9 million |
| Gross profit / margin | $162.7 million / 39% | $161.7 million / 40% |
| Operating income (loss) | $0.6 million | ($3.8 million) |
| Net loss | ($16.4 million) | ($23.9 million) |
| Net loss per share | ($0.19) | ($0.28) |
| Cash from operations | ($29.6 million) | $18.3 million |
- Product revenue was $196.7 million, up 7%; service revenue was $222.1 million, up 1%. TomoTherapy system sales increased, while CyberKnife system sales declined.
- Product gross margin fell to 41% from 44%, which management attributed principally to a higher mix of lower-margin Radixact systems. Service gross margin was 37% in both years.
- FY2019 operating cash use reflected, among other items, a $46.2 million increase in accounts receivable and a $14.2 million increase in inventory. Investing activities used $4.3 million, primarily for property and equipment; financing activities provided $28.5 million, principally from debt borrowing.
- At June 30, cash and cash equivalents were $76.8 million, restricted cash was $11.4 million, and working capital was $151.9 million. Management said available cash, debt facilities, and expected cash flows should fund operations for at least 12 months.
- Debt had a $159.8 million carrying value and $176.3 million principal balance: $85.0 million of 3.75% convertible notes, $63.0 million term-loan principal, and $28.3 million revolver borrowings. The credit facilities include financial covenants and collateral provisions.
- Backlog was $495.6 million, versus $478.5 million a year earlier. FY2019 gross orders were $342.3 million and net orders were $218.3 million; net age-outs were $95.5 million and cancellations were $25.0 million.
- FY2019 Q4 revenue was $117.4 million, gross profit was $45.9 million, and net loss was $1.4 million.
Material changes and comparability
- Revenue increased 3% as reported, but FY2019 included adoption of ASC 606 using the modified retrospective method. The filing estimates FY2019 revenue would have been $380.9 million without ASC 606, versus $418.8 million reported; the new standard also reduced reported FY2019 net loss by $21.0 million relative to the prior accounting basis. FY2018 was not restated, so reported year-over-year figures are not fully comparable.
- Revenue growth was led by TomoTherapy systems: product revenue rose $12.8 million overall, including a $34.0 million increase in TomoTherapy sales, partly offset by a $19.5 million decrease in CyberKnife sales.
- Gross margin declined one percentage point. Operating expenses fell to $162.1 million from $165.5 million, including lower selling and marketing expenses; operating results moved from a $3.8 million loss to $0.6 million income.
- Cash from operations deteriorated by $47.9 million year over year, and cash and cash equivalents declined $6.3 million. The company also reported higher accounts receivable, inventory, and bad-debt expense.
Outlook, risks, and unusual items
- Outlook: Management expected FY2020 R&D expense to be slightly lower than FY2019, selling and marketing expense slightly higher because of launches and added headcount, and G&A expense lower, partly reflecting an expected reduction in bad-debt expense. No specific revenue or earnings guidance is provided in the supplied filing text.
- Accuray expected to ship Radixact Synchrony to selected evaluation sites through calendar 2019, with broader commercial launch expected in early 2020. These are forward-looking expectations, not guaranteed outcomes.
- In January 2019, Accuray formed a China joint venture with an initial 49% company ownership. Its initial contribution was expected to include components for two systems, with contributions staged through December 2019. The JV had obtained operating permissions and begun selling products in China by the filing date; local manufacturing was a longer-term aim.
- Key risks include long and variable sales, installation, and revenue-conversion cycles; cancellations and aged-out backlog; reliance on international distributors and single-source suppliers; competition and technology shifts; reimbursement and regulatory changes; trade tariffs affecting China-sourced components and products; and foreign-exchange exposure.
- Liquidity and leverage warrant attention: the company used operating cash, has substantial debt and covenant requirements, and noted that covenant waivers or amendments might be needed in some circumstances. Management’s 12-month liquidity assessment is an expectation subject to business and market risks.
- Accuray disclosed three voluntary CyberKnife recalls opened in FY2019: one was closed, one had been submitted for closure and was under FDA review, and one remained in progress at June 30, 2019. The company reported no serious adverse health consequences and said recall costs were not material. A separate TomoTherapy recall from FY2018 had been submitted for closure.
- Other notable items included a $1.5 million workforce-reduction charge affecting approximately 5% of global employees and a $2.2 million expense for a terminated project. The financial statements received an unqualified audit opinion; management and the auditor reported effective internal control over financial reporting.
Most important facts for investors to verify
- Reconcile the ASC 606 impact when comparing FY2019 revenue, loss, and margins with FY2018; confirm the timing effects on system revenue and capitalized contract-acquisition costs.
- Track collections, receivable quality, bad-debt provisions, inventory levels, and whether operating cash flow improves after FY2019’s substantial working-capital use.
- Assess conversion of backlog into revenue, especially the large age-outs and cancellations, and distinguish backlog from GAAP revenue.
- Review debt principal, variable-rate exposure, covenant compliance, repayment terms, and the assumptions supporting management’s liquidity outlook.
- Monitor Radixact and CyberKnife demand and margins, Synchrony’s commercial launch, China JV investment and licensing progress, and the status of disclosed recalls.